Background: Digestive disorders in weaning pigs remain a major challenge for swine producers. Different types of commercial feed additives have been developed to promote gut health and development in young pigs, but their effects on resident gut microbial communities remain largely unexplored. The aim of this study was to investigate the impact of a peptide-based product (Peptiva) in combination with mannose oligosaccharides (MOS) and an exogenous protease on the performance and fecal microbiome of nursery pigs.

Methods: A total of 1097 weaned pigs were divided into 44 pens (24-26 pigs/pen) with each pen randomly assigned to one of four experimental diets as part of Phase II and Phase III of a standard nursery phase feeding program. Fecal samples collected from representative control and treatment pigs were used to investigate bacterial composition profiles by high throughput sequencing of PCR-generated amplicons targeting the V1-V3 region of the 16S rRNA gene.

Results: Higher gain:feed was observed for pigs fed Peptiva and MOS compared to Controls during the period when experimental diets were fed, but the benefits of supplementation were not maintained after pigs were transitioned to a non-supplemented diet. Three candidate bacterial species, identified as Operational Taxonomic Units (OTUs), were found to have significantly different abundances between control samples and treatment samples during the same phase. In Phase III samples, SD_Ssd-00039, predicted to be a strain of Streptococcus alactolyticus based on nucleotide sequence identity, was the most highly represented of these OTUs with an average abundance in pigs fed Peptiva, MOS and protease that was 3.9 times higher than in Controls. The report also presents evidence of microbial succession that occurred during the trial, with 16 of the 32 most abundant OTUs found to vary between Phase II and Phase III samples for the same dietary treatment.

Conclusions: Dietary supplementation with a combination of a peptide-based product, MOS, and protease increased the growth performance of weaned pigs compared to control animals during the nursery phase, but these benefits were no longer observed within 2 weeks after all animals were transitioned to a non-supplemented diet. Supplementation with these feed additives was found to modulate the composition of the swine gut microbiome during this period.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928611PMC
http://dx.doi.org/10.1186/s40104-022-00681-8DOI Listing

Publication Analysis

Top Keywords

mos protease
12
feed additives
12
weaned pigs
12
phase phase
12
phase iii
12
pigs
9
growth performance
8
performance fecal
8
peptide-based product
8
experimental diets
8

Similar Publications

Real-Time and Ultrasensitive Prostate-Specific Antigen Sensing Using Love-Mode Surface Acoustic Wave Immunosensor Based on MoS@CuO-Au Nanocomposites.

Sensors (Basel)

November 2024

Shenzhen Key Laboratory of Advanced Thin Films and Applications, GuangDong Engineering Technology Research Centre of Breath Test, College of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen 518060, China.

Prostate-specific antigen (PSA) is a well-established tumour marker for prostatic carcinoma. In this study, we present a novel, real-time, and ultrasensitive Love-mode surface acoustic wave (L-SAW) immunosensor for PSA detection enhanced by MoS@CuO-Au nanocomposite conjugation. The MoS@CuO-Au nanocomposites were analyzed by SEM, XRD, and EDS.

View Article and Find Full Text PDF

Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated Proteins (CRISPR/Cas) system can accurately identify and cleave target DNA sequences, while the effective combination of DNA nanomatrix and entropy-driven self-assembled enzymes can significantly enhance the sensitivity, stability, and diversified functionality of sensors through highly ordered molecular arrangement and spontaneous efficient assembly processes. Herein, a carbon-encapsulated MoS hollow nanorod (C-MoS) with excellent conductivity and multiple active sites is used to construct bioanode of biofuel cell by integrating it with an entropy-driven self-assembled enzyme-DNA nanomatrix cascade DNAzyme-CRISPR/Cas system. When thrombin binds aptamer, it exposes the trigger strand on the anode, initiating chain displacement.

View Article and Find Full Text PDF

Exploring Selective Fluorescence Turn-On Sensing of Caspase-3 with Molybdenum Disulfide Quenched Copper Nanoclusters: FRET Biosensor.

ACS Appl Mater Interfaces

November 2024

Department of Chemistry, School of Physical and Mathematical Sciences, University of Kerala, Kariavattom Campus, Thiruvananthapuram 695581, Kerala, India.

Sensing caspase-3 activity is essential for understanding the role of apoptosis in cancer dynamics, controlling therapeutic strategies, and improving patient care in cancer treatment. In this study, we demonstrate a highly sensitive recombinant human caspase-3 (rhC3) detection technique in biological fluids. This technique uses a copper nanocluster stabilized with bovine serum albumin (BSA-CuNCs) as a metal-based fluorescent biosensor, conjugated with anti-human caspase-3 (ahC3).

View Article and Find Full Text PDF

This study describes a novel dual-mode immunosensor that combines electrochemical (EC) and surface-enhanced Raman scattering (SERS) techniques for the detection of prostate-specific antigen (PSA), a biomarker associated with prostate cancer. The sensor consists of a nanocomposite of gold nanoparticles (AuNPs) deposited on two-dimensional (2D) molybdenum disulfide (Au@MoS) modified on a working carbon electrode of a screen-printed electrode (SPE). Subsequently, the primary antibody (Ab1) is immobilized on the modified electrode, creating Ab1/Au@MoS/SPE for specific recognition of the target PSA.

View Article and Find Full Text PDF

Purpose: Enzalutamide after abiraterone progression is commonly used in metastatic castration-resistant prostate cancer despite a low rate of clinical benefit. Analyzing IMbassador250, a phase III trial assessing enzalutamide with or without atezolizumab after abiraterone, we hypothesized that baseline and early changes in circulating tumor DNA (ctDNA) tumor fraction (TF) may identify patients more likely to exhibit survival benefit from enzalutamide.

Experimental Design: ctDNA was quantified from plasma samples using a tissue-agnostic assay without buffy coat sequencing.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!